May 06, 2022 08:00 AM

Shenzhen Hepalink Pharmaceutical Group Co.,Ltd.’s Net Profit Rose 64.9% in First Quarter of 2022

By Caixin Automation

Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (深圳市海普瑞药业集团股份有限公司) (002399.SZ) reported a net profit of 235.2 million yuan in the first quarter of 2022, up 64.9% year-on-year.

Meanwhile, the company posted 1.9 billion yuan in revenue, up 50.7% year-on-year.

At the end of the reporting period, it had 20.1 billion yuan in total assets and 8.4 billion yuan in total liabilities, with a liability-to-asset ratio of 41.6%.

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Innovation Takes Off at Flying Vehicle Expo

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin Deep Dive: How China’s Crypto Ban Makes Disposing of Seized Assets a Lot Harder

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s Factory Exodus Is Turning Vietnam Into the World’s Assembler

2: Meituan Enters Open-Source AI Race With LongCat Model

3: Ex-UBS Banker in Hong Kong Jailed 10 Years for Laundering $17.2 Million

4: End of U.S. Tax Exemption Hits Chinese Air Cargo Carriers Differently

5: China Rolls Out Subsidized Consumer Loans to Boost Spending

SPONSORED

OR